Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Sounds of Science and Charles River. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sounds of Science and Charles River or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Off-Target, On-Point: How Retrogenix® Reduces Risk and Animal Use

28:05
 
Share
 

Manage episode 503963096 series 2304454
Content provided by Sounds of Science and Charles River. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sounds of Science and Charles River or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA’s ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O’Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.

Show Notes

  continue reading

101 episodes

Artwork
iconShare
 
Manage episode 503963096 series 2304454
Content provided by Sounds of Science and Charles River. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sounds of Science and Charles River or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of Sounds of Science, learn how the Retrogenix® platform is reshaping drug development by identifying off-target risks earlier, reducing animal use, and gaining traction with regulators—now as part of the FDA’s ISTAND pilot program. Guests Nick Brown and Mark Aspinall-O’Dea from Charles River Discovery Services share real-world insights on their role in advancing NAMs and supporting safer, faster therapeutic development.

Show Notes

  continue reading

101 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play